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Abstract  
Introduction  
Registration of medicines is an essential function of the national medicine regulatory system 
of any country. Since the start of the medicine registration system in Tanzania in early 2000s, 
no systematic review has been carried out to document the status of the system and its impact 
on availability and access to quality assured medicines to the people of Tanzania.   
Objectives 
The study was aimed at reviewing the medicine registration system in Tanzania as 
implemented by the Tanzania Food and Drugs Authority in order to  come up with  status of 
the medicine registration system implemented in Tanzania, and evaluate how the system 
contributes to the availability and access of essential medicines, particularly those needed to 
support the essential medicines lists and standard treatment guidelines.  
Methods 
A descriptive cross sectional survey was used to review the system for registration of 
medicines in Tanzania before and after implementation of CTD guidelines. The study 
involved the review of medicine registration system for the period of one year prior to and 
two years of implementation of CTD guidelines (July 2015 – June 2017) and data on a total 
of 250 medicines which were received, reviewed and approved during this study period was 
reviewed.  
Results 
Tablets were the most commonly registered dosage forms across the study period and India 
and China were the most dominant suppliers of active pharmaceutical ingredients as well as 
finished products registered in Tanzania. Alarmingly, a decreasing trend was observed in 
terms of registration of medicinal products which are prescribed in the Standard Treatment 
Guidelines. Results of this study have also revealed that generic medicines are still the 
predominant type of medicines with all the medicines (100%) registered between the year 
2015 – 2017 being generic medicines and between 94 – 100% of those registered medicines 
from chemical medicines category. Only 4% of medicines were indicated for  use in 
pediatrics’, with the majority of the medicines (71%) indicated for the use in both children 
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and adults. Conformance of manufacturers with requirements for registration of medicines 
was low in the areas of synthesis and manufacture of active ingredients as well as control of 
quality while with respect to finished products, the majority of deficiencies were observed in 
the choice of container closure systems followed by stability testing. Introduction of CTD 
guidelines has had a positive impact on registration timelines, review timelines have 
decreased from above 400 days to as low as just above 200 days. 
 
Conclusion 
Findings of this study have highlighted the status of medicine registration system in 
Tanzania. Despite the implementation of CTD guidelines by TFDA, similar patterns in parts 
of medicinal products dossiers with deficiencies have been noted across the study years. The 
observed deficiencies demonstrate a weakness in the preparation of marketing authorization 
applications on the side of the applicants. It is recommended that findings of this study 
should be used in strengthening the medicine registration system in Tanzania, particularly 
with respect to capacity building of manufacturers in fulfilling medicine registration and 
GMP requirements.  
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CHAPTER ONE 
 
INTRODUCTION 
 
Medicines are substances specifically recognized by an official Pharmacopeia and Formulary 
that are approved for use to treat, diagnose, cure or prevent a disease or disorder. According 
to Tanzania food, drugs and cosmetics act (2003), a medical substance induces changes to the 
function or structure of the patient’s body. Based on the nature and function of the medicines 
it has long been recognized that medicines are among the highly regulated products and they 
are not ordinary consumers’ products. In most instances, consumers are not in a position to 
make decisions about when to use medicines, which medicine to use, how to use them and to 
weigh potential benefits against risks as no medicine is completely safe, without professional 
advice from healthcare professionals (Rago et al, 2008).  
Health budgets in the developing countries are generally small, when compared to developed 
countries, and 30-40% of the total health budget is spent on medicines and other medical 
supplies (Kazeem, et al, 2011). Considering the small amount of funds available for drugs in 
these poor countries, it is desirable that countries and international donor communities 
purchase medicines including essential medicines that are of acceptable quality, safety and 
efficacy 
The regulation of medicines is crucial to the health and safety of the public since it is the tool 
that ensures that medicines of high quality are manufactured, stored and distributed in the 
given country. High quality ensures safety and efficacy of the respective medicines and hence 
ensures protection and promotion of public health.   
Medicines regulation involves a range of related activities including interactions with various 
stakeholders with different economic, social and political motives. This makes the 
implementation of regulation by National Medicines Regulatory Agencies (NRAs) both 
politically and technically challenging in many parts of the world.  Minimum regulatory 
functions include licensing of the manufacture, import, export, distribution, promotion and 
advertising of medicines; assessing the safety, efficacy and quality of medicines;, inspecting 
and surveillance of manufacturers, importers, wholesalers and dispensers of medicines; and 
issuing marketing authorization for individual products. Other important functions involve  
http://etd.uwc.ac.za/
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controlling and monitoring the quality of medicines on the market, controlling promotion and 
advertising of medicines, monitoring safety of marketed medicines including collecting and 
analyzing adverse drug reaction reports, and providing independent information on medicines 
to professionals and the public (Rago et al, 2008). 
 
The importance of regulating medicines comes from the fact that the use of ineffective, poor 
quality, harmful medicines can result in therapeutic failure, progression of disease conditions, 
and development of resistance to most lifesaving medicines and sometimes death (WHO, 
2003). Money spent on ineffective, unsafe and poor-quality medicines is wasted whether by 
patients, insurance companies or governments. Therefore, countries have set up medicines 
regulation systems which involves medicines registration, inspection of manufacturing 
facilities where the respective medicines are manufactured and tested and post marketing 
surveillance for safety and efficacy of the respective medicines. 
Regulation of medicines is a national responsibility and it is carried out by the Ministry of 
Health, and in many countries the role is assigned to the National Medicine Regulatory 
Agency. According to the World Health Organization, national medicine regulatory agencies 
contribute to protecting and promoting public health by ensuring that medicines are of the 
required quality, safety and efficacy. They also ensure that health professionals and patients 
have the necessary information to enable them to use medicines rationally, that medicines are 
appropriately manufactured, stored, distributed and dispensed, that illegal manufacturing and 
trade is detected and adequately sanctioned, that promotion and advertising is fair, balanced 
and aimed at rational drug use and that access to medicines is not hindered by unjustified 
regulatory work. 
Registration of medicines is an essential  function of the national medicine regulatory system 
of any country,  and is also known as product licensing or marketing authorization.  In 
principle, all medicines that are marketed, distributed and used in the country should be 
registered by the national competent regulatory authority. The process of registration includes 
the scientific evaluation of product to ensure that it meets the criteria for safety, efficacy and 
quality.  
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CHAPTER TWO 
LITERATURE REVIEW 
 
The primary aim of medicine regulation and in particular medicine registration is protection 
of the public's health. However, Al-Essa et al. (2015) who reviewed medicine regulatory 
systems in the gulf region revealed that regulation is often perceived as an obstacle to the 
availability of medicines in national or regional markets. This view has placed a significant 
demand on regulators to accelerate reviews and evaluations to approve new medicines in the 
shortest possible time and to expedite the review and ensure continuous safety and efficacy of 
the marketed medicine. 
The evaluation process has often been perceived as lengthy and it is often cited as one of the 
major factors affecting access to essential medicines especially in developing countries. A 
report published by Management Sciences for Health (2017) highlighted that in developing 
countries, new chemical entities, generic medicines, new fixed-dose combination products, 
and innovative new products, including important antimalarials and antiretroviral medicines 
for HIV/AIDS are subject to prolonged registration times compared to other categories of 
important medicines.     
In Tanzania, the registration of medicines is a legal requirement prescribed in Section 51 of 
the Tanzania, Food, Drugs and Cosmetics Act 2003; Cap 219. The act mandates the Tanzania 
Food and Drugs Authority (TFDA) to register all medicines before they are allowed to 
circulate on the Tanzania market with the conditions for registration of medicines specified 
as: compliance of manufacturing sites with GMP requirements, proven safety, efficacy and 
required quality and whether the availability of the medicine applied for registration is of 
public interest (TFDA 2013). 
The medicines registration process as implemented by TFDA since its establishment in the 
year 2003 involves the following sequential steps:  receiving of applications, evaluation of 
scientific data submitted to demonstrate quality, safety and efficacy of the medicine, 
conducting quality control tests of medicine samples submitted, conduction of inspection of 
manufacturing facilities to verify compliance to good manufacturing practice standards 
(GMP) and eventually approval and issuance of certificates of registration. 
http://etd.uwc.ac.za/
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Since the start of the medicine registration system in 2003, the TFDA has registered more 
than 5300 medicinal products, many of which are generic products manufactured by both 
foreign and domestic manufacturers. According to TFDA’s ten years’ anniversary report 
(2013), there has been an overall increase in the number of registered medicines every year.  
Currently registration of medicines in Tanzania is carried out through the implementation of 
CTD guidelines for registration of medicines as harmonized with other partner states within 
the East African Community (EAC). These harmonized guidelines were adopted by TFDA 
with effect from 1st July 2015 as part of the Harmonization process within the EAC Partner 
States. In the process of development of Harmonized EAC guidelines, ICH CTD and WHO 
documents were used as templates in an attempt not to deviate from the world’s major 
regulators, international standards as well as best regulatory practices.  
Despite its usefulness, the medicine registration system has for long been cited as a technical 
barrier to the access of essential medicines especially in resource limited countries. As is the 
case in other developing countries, the medicine registration system of Tanzania has not been 
significantly studied to identify the spectrum of factors that affect the performance of the 
respective systems despite various reports of these systems functioning below the optimum 
requirements. In addition, the contribution of the medicine registration systems to the 
availability and access of essential medicines, lists and standard treatment guidelines have not 
been clearly explored in the context of developing countries, particularly the African context.  
 
Different regulators in the world have established different timelines for the assessment and 
approval of medicines based on intuition. In addition different assessment practices and 
pathways have been designed in order to make medicine registration systems more efficient. 
A study by Reem et al. (2015) conducted to study medicine registration timelines in Gulf 
countries revealed varying medicine registration timelines across the respective countries. In 
that study, it was also demonstrated that there was a significant reduction in the timelines 
because of harmonization and application of alternative mechanisms such as parallel 
approvals and fast track application routes.  
 
Moreover, it is recognized that among regulators that, timely completion of assessments and 
approval of medicines requires the cooperation of the manufacturers in fulfilling the 
requirements, including submission of medicine registration applications that are compiled 
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according to the requirements. Studies by Ortega et al. (2014) and Worku et al. (2012) 
demonstrated deficiencies in the fulfillment of medicines registration requirements in the 
dossiers of API and FPP submitted for assessment in WHO Prequalification programme 
respectively. From the studies, the authors recommended the need for continued capacity 
building of local generic manufacturers, further development of pharmacopoeia monographs 
and promotion of development of generic products as well as new guidelines.  
 
Since the start of medicine registration system in Tanzania in the early 2000s, no systematic 
review has been carried out to document the status of the system. Thus, evidence on the 
actual contribution of medicines registration systems to the availability of essential medicines 
in this country has not been well documented, and the actual time taken to register medicinal 
products have not been well characterized. In the absence of a systematic review of the 
system, it is also currently not possible to determine the contribution of the manufacturers 
with regards to facilitation or hindrance of access to medicines in Tanzania from the 
regulatory point of view. 
This study was aimed at reviewing the medicine registration system in Tanzania as 
implemented by Tanzania Food and Drugs Authority. The expectation from the study was to 
evaluate the  status of the medicine registration system implemented in Tanzania, particularly 
on the way that  the system contributes to the availability and access of essential medicines. 
The broad objective of this study was to review the system for registration of medicines in 
Tanzania. Specifically the study was aimed at assessing; trends in registration of medicines in 
Tanzania in line with Tanzania Essential Medicines Lists and standard treatment guidelines, 
conformance of applicants for registration of medicines to technical requirements for 
registration and timelines for registration of medicines in Tanzania.  
It is expected that the findings of this study will better inform all stakeholders on the current 
status and provide recommendations for further improvements of the system. The findings of 
this study will also provide baseline information on medicines registration systems in the 
context of developing countries. 
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CHAPTER THREE 
 
METHODOLOGY 
 
 
3.1  Study Area 
 
The study was conducted within the Directorate of Medicines and Complementary Products 
in the Tanzania Food and Drugs Authority. The directorate hosts the Section for Registration 
of Human and Veterinary Medicines Registration, the section carries out evaluation and 
registration of Human and Veterinary medicines, maintains medicine registers and manages 
the lifecycle of registered medicines including post-registration amendments (variations) and 
renewal of registrations.  
 
3.2 Study Design 
A descriptive cross sectional survey was used to review the system for registration of 
medicines in Tanzania before and after implementation of CTD guidelines. Therefore, the 
study involved the review of medicine registration system for the period of one year prior to 
and two years post implementation of CTD guidelines (July 2015 – June 2017). 
3.3 Study data 
 
The data was obtained from the medicine application database, the medicine registration 
database and medicine registration assessment reports repositories. The medicine registration 
database used at TFDA is managed through the web based Management information system 
(MIS) that is used for management of medicine registration applications as well as in other 
support functions. The database contains administrative information, brand and generic 
names, information on active pharmaceutical ingredients, dosage forms, routes of 
administration, and information on manufacturers of both APIs and FPPs. The database also 
includes registration numbers as well as product validity information.  
 
For the purpose of assessing conformance of applicants with medicine registration 
requirements, medicine assessment reports for the studied applications were obtained from 
http://etd.uwc.ac.za/
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the repositories for assessment reports. Questions raised by the assessors found in the 
sections of the assessment reports were counted and number of questions were entered into 
data collecting tool. 
3.4 Sample size 
 
During the review period, a total of 2700 applications for registration of  human medicines 
were received, out of which 250 were registered. Out of the medicinal products registered in 
the review period, 137 were of applications received before the implementation of CTD and 
113 were of applications received after the implementation of CTD guidelines. Therefore, the 
study involved the review of the registration process of all 250 human medicines that were 
received, reviewed and registered during the study period.   
 
3.5 Sampling technique 
 
Convenience sampling was used in which all the 250 applications for registration of 
medicines that were received, reviewed and registered between July 2014 and June 2017 
were included in the review.  
 
3.6 Data Collection 
 
3.6.1 Data Collection Tool 
 
A special data collection tool (Annexure I) was used to collect the required information on 
the medicine registration applications to be included in the study. The tool was divided into 
four major parts of which Part A was intended at collecting general and administrative 
information about the studied applications, Part B was used to capture the information on 
trends in applications and registration. Part C was used to collect information on deficiencies 
observed during assessment of the applications and Part D was used to capture the 
information about registration timelines including regulator’s time and applicant’s time.  
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3.6.2 Pre-testing of Tool 
 
The data collection tool was tested for suitability and usability on 10 intended applications to 
be reviewed. It was then amended, refined and reviewed before commencement of the actual 
data collection process.    
 
3.6.3 Data collection procedure 
 
Two (2) research assistants were trained on the objectives and methodology of the study and 
they used the data collection tool to collect the data from the identified data sources within 
the Human and Veterinary Medicines registration section at TFDA Headquarters.  The entire 
data collection activity was done in the month of August 2017 and it was closely monitored 
and supervised by the investigator.  
3.6.4 Quality control of data collection 
 
Electronic copies of the filled in data collection tools were collected from the research 
assistants and checked for correctness and consistency by the investigator.  
 
3.7 Data Analysis 
 
The data from the tool was entered in Microsoft excel program and analyzed by current 
versions of Microsoft excel software for means and proportions. Conformance of the 
applicants with the requirements of medicines registration as prescribed in the guidelines for 
submission of applications for registration of medicinal products was evaluated based on the 
extent to which data submitted in medicinal products dossiers did meet the requirements at 
the first round of assessment. To achieve this, assessor’s comments/questions were reviewed 
and tallied on each of the quality parts of the active pharmaceutical ingredient (API) and 
quality of the finished pharmaceutical product (FPP). 
3.8 Ethical Considerations 
 
Permission to conduct the study and use the data was sought from TFDA management and 
research assistants were made to fill in confidentiality undertakings which were kept in the 
relevant file at TFDA. Efforts were made to ensure that no proprietary information or trade 
secrets contained in the source data were included in the final report. 
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CHAPTER FOUR 
 
RESULTS 
 
4.1. General information 
 
4.1.1 Types of dosage forms registered 
 
Tablets were the most registered type of dosage form of medicines compared to other dosage 
forms registered in Tanzania. The second most registered type of dosage form was solutions 
for injections and external/topical preparations. There was a general trend with respect to 
pessaries and suppositories registered during the study period (2014 – 2017) where the data 
show very little or no registration of this type of dosage forms.   
 
Table 4.1  Trends in proportions of different types of dosage forms of medicines 
registered over the course of review period.  
 
Dosage form/type Percentage registered per year 
2014 2015 2016 2017 Overall 
Tablets 47 52 41 47 48 
Capsules 8 0 10 0 6 
Solution for 
Injection 
9 20 10 13 13 
Dry powder for 
Injection 
8 0 7 13 6 
Dry powder for 
oral suspension 
7 6 7 0 6 
External/Topical 
preparations 
5 7 10 7 7 
Pessaries 1 0 0 0 0 
Suppositories 1 0 0 0 0 
Syrups 1 1 0 1 1 
Nasal drops 1 0 3 0 1 
Eye/ear drops 2 7 7 13 5 
Inhalers 3 0 0 7 2 
Solutions for 
Infusions 
5 6 3 0 5 
Emulsion for 
Injections 
 
1 
 
0 
0 0 0 
Granules 1 0 0 0 0 
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4.1.2 Distribution of registered medicines based on country of supply of active 
ingredients 
At an overall contribution of 53% over the four years period, India was the number one 
contributing country of the active pharmaceutical ingredients used to manufacture the studied 
medicines followed by China (14%) and Switzerland (6%). Notably none of the API supplies 
used to manufacture the medicinal products included in the study had been sourced from 
Tanzania and the African continent in general (see figure 4.1). 
 
 
 
Figure 4.1: Distribution of country of origin of suppliers of active pharmaceutical ingredients 
(APIs) used to manufacture the reviewed medicines  
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4.1.3 Distribution of registered medicines based on country of manufacture 
 
Medicinal products registered between the year 2014 – 2017 were from manufacturers located in a total 
of 27 countries. Out of these, India was the leading country with 54% of finished products originating 
from this particular country followed by Germany which contributed 5.6% of the finished 
pharmaceutical products. Other countries that had significant contributions to the number of medicinal 
products registered include Tanzania which contributed 4% of all medicinal products, Austria (2.6%), 
Kenya (3.3%), United States of America (2.6%) and Slovenia which contributed 3.3%.  The United 
Kingdom, Belgium and Bangladesh had the least number of registered medicines with each one of the 
countries contributing around 1% of all registered medicines (see figure 4.2).  
 
 
2.5 2.2
1.9
5.6
54.4
1.1
1.9
3.3
2.6
4.4
2.6
1.9
1.5 3.3
1.5 1.1 1.1
1.5
Proportion of registered finished medicinal products based on 
country of manufacture
Austria Switzerland China Germany
India Italy Poland Slovenia
Spain Tanzania USA France
Netherland Kenya Bangladesh Ukraine
Kingdom of Saudi Arabia South Africa
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Figure 4.2: Distribution of registered medicines based on the country of manufacture  
 
4.1.4 Distribution of registered medicines based on availability in standard 
treatment guidelines 
 
The products were also assessed with respect to their availability on the standard treatment 
guideline (STG). In 2014, 60% of the medicinal products registered were also available in the 
standard treatment guidelines (STG) for Tanzania and 40% were not in the STG document. In 
2015, 41% of the registered medicinal products were in the STG and 59% were not, whereas 
in 2016, only 11% of the registered medicinal products were on STG and 89% were not in 
the STG. For the period of January to June 2017 all medicinal products granted registration 
were not listed in the standard treatment guidelines for Tanzania. 
 
4.1.5 Registration based on type of medicine and proportions registered 
 
Generic medicines  made up 89% of the medicinal products registered in 2014, while in the 
subsequent years of study period (2015 -2017) all the registered medicinal products (100%) 
were generics. There was a decreasing trend in number of medicinal products registered over 
the years during the study period with 54%  of the medicines registered in 2014,  followed by 
28% in 2015, 13% in 2016 and only 5% of the medicinal products registered in 2017. 
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Figure 4.3: Distribution of registered medicines based on year of approval 
 
4.1.6 Registration based on category of medicine 
 
Generally four major categories of medicinal products were registered between 2014 – 2017, 
these categories were chemical drugs, vaccines, immunological products and biosimilars.  
 
Table 4. 2:   Distribution of registration of these four categories of medicines across the 
study period 
Category of Drug 
Product 
                          Year  
Percentage registered per year 
2014 2015 2016 2017 
Chemical 97 97 94 100 
Vaccine 0 1.5 6 0 
Immunological 0 0 0 0 
Biosimilar 3 1.5 0 0 
 
The overwhelming  majority of registered medicines over the study period were chemical 
medicines with vaccines and Biosimilars constituting a small minority. During the study 
period, no Immunological medicines were registered. Notably all the medicines registered up 
to June 2017 were chemical medicines.  
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4.1.7 Registration based on intended age group 
 
With regards to intended age group for which the medicines are registered, the majority of 
the medicines registered in the year 2014 were indicated for both adults and children (53%) 
with 40% indicated only for adults (40%), and 7% indicated for pediatric age groups only.  
 
In the year 2015, only 1% of medicinal products registered were specifically indicated for the 
use in children while products indicated for both age group were as many as 93% of the 
products. The rest were those indicated for adults only. The data shows that from the year 
2016 and up to June 2017 none of the medicinal products registered were indicated for the 
use in children only. In 2016, 11% of registered medicines were indicated for adults only 
while up to June 2017, only 7% of the registered medicines  were indicated for adults only. 
Rest of the products in these years were for the use in both adults and children.  
 
 
 
 
 
 
Figure 4. 4:  Distribution of medicines registered by indicated age group. 
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4.2 Conformance of the applicants with medicine registration requirements  
 
4.2.1 Conformance on requirements for quality of active pharmaceutical 
ingredients   
For the dossiers which were submitted and registered in the year 2014, the majority of the 
deficiencies (67%) were in the nomenclature and properties of the API,  25% of the 
deficiencies were in the manufacture of the API, and 8% were in the characterization of 
potential impurities in the API (table 3).  
 
In the year 2015, 24% of the deficiencies were in container closure system followed by the 
stability studies on the API (17%) and 14% of deficiencies were on control of critical steps 
and intermediates (table 3). In 2016, 36% of all the deficiencies were on analytical 
procedures and validation, followed by 24% on the API manufacturing process (narrative, 
flow diagrams and control of intermediates and critical steps) and 10% were on nomenclature 
and properties of the API (table 3).  
 
For medicinal products which were registered up to June 2017, 28% of all the deficiencies 
were from description of API manufacturing process, 24% were from API specification and 
analytical procedures and validation and 12% were from the nomenclature and properties of 
the API (table 3). 
Table 4.3:    Proportions of nonconformances with medicine registration requirements 
for API across the study period  
 
API dossier 
section 
Percentage number of questions across CTD sections 
2014 2015 2016 2017 
3.2.S.1 67 5 10 12 
3.2.S.2.1 25 2 0 0 
3.2.S.2.2 0 4 24 28 
3.2.S.2.3 0 12 0 0 
3.2.S.2.4 0 14 7 0 
3.2.S.3.1 0 0 5 0 
3.2.S.3.2 8 3 5 4 
3.2.S.4.1&4.5 0 7 2 24 
3.2.S.4.2 &4.3 0 1 36 24 
3.2.S.4.4 0 2 3 0 
3.2.S.5 0 9 5 0 
3.2.S.6 0 24 5 4 
3.2.S.7 0 17 5 4 
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4.2.2 Conformance on requirements for quality of finished pharmaceutical 
products   
On compliance of medicine registration requirements for finished pharmaceutical products, in 
the year 2014, more than 33% of the deficiencies were observed on the data to demonstrate 
suitability of the container closure system, 17 % of the deficiencies were from stability of 
FPP and 10% of the deficiencies were from control of quality of the finished pharmaceutical 
products (i.e. specifications, analytical procedures including validation as well as batch 
analyses) (see table number 4).  
 
For the year 2015, the highest proportion of deficiencies (26%) were observed from the 
requirements for demonstration of suitability of container closure system of the FPP followed 
by deficiencies in stability data (19%) and control of quality of the finished product 
(specifications, analytical procedures, validation and batch analysis) with 16% of the 
deficiencies (see table 4). Similarly, for the dossiers submitted and products registered in the 
year 2016, the highest proportion of deficiencies were observed in the demonstration of 
suitability of container closure system (13%). These were followed by deficiencies on 
validation of analytical procedures which contributed 10% of the deficiencies (table 4). In 
2017, 31% of the deficiencies were from container closure system information of FPP, 21% 
were from manufacture information FPP and 14% were from control of the FPP (table 4).  
 
Table 4.4:   Proportions of nonconformances with medicine registration requirements for 
finished pharmaceutical products across the study period  
 
API dossier 
section 
Percentage number of questions across CTD sections 
2014 2015 2016 2017 
3.2.P.1 1 3 1 3 
3.2.P.2 5 1 0 2 
3.2.P.3 10 3 1 21 
3.2.P.4 7 9 2 8 
3.2.P.5.1 9 20 1 14 
3.2.P.5.2 2 1 6 0 
3.2.P.5.3 5 5 10 0 
3.2.P.5.4 5 7 5 5 
3.2.P.5.5 1 0 9 0 
3.2.P.6 1 8 9 8 
3.2.P.7 33 26 33 31 
3.2.P.8 16 16 13 3 
Bioequivalence 4 2 10 5 
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4.3 Medicine registration timelines 
Registration timeline is the measure of time taken from the day that an application for 
registration of a medicinal product is lodged to the day that the product is registered and 
issued the marketing authorization in Tanzania. Overall registration timelines were calculated 
to include the total amount of time the application has spent in the registration process in 
TFDA and the time the application has stayed with the applicant where additional data has 
been requested.  
 
For applications that were submitted and registered in the year 2014, median registration time 
from the time that the application is submitted to the time that the product is granted 
registration was 401 days. A decrease in the median registration time was observed in the 
other consecutive study periods, with the median registration time in 2015, 2016 and 2017, 
397, 362 and 217 days respectively. Figure number 4. 5 below shows the trends in median 
registration time over the years for medicine registration applications falling within the study 
period. 
 
 
 
 
Figure 4.5:  Trend in registration timelines (days) across the years in study period  
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CHAPTER FIVE 
     DISCUSSION 
  
Tablets were by far the most common registered dosage form, followed by solutions for 
injections and dry powder for injections. This observation is consistent across medicines 
registered in all four years of the study period, and correlate with the recommendations in 
Standard Treatment guidelines for Tanzania where tablets are the most preferred 
treatment options for most disease conditions (MOHCDGEC, 2017). With such assured 
market, most registrants would be attracted to registering the most preferred dosage form 
of their medicine which is tablets. 
 
The study findings also indicates a bias towards medicines manufactured outside the 
country with India accounting for 54% of all medicines registered within the study period 
and only 4% locally manufactured in Tanzania. A report published by Businessworld 
(2018) indicated that currently India holds the third position in global pharmaceutical 
exports amounting up to 20 billion dollars. Findings of this study probably reflect from 
the fact that the standard treatment guidelines for Tanzania advocates for the use of 
generic names in prescribing and dispensing of medicines in the country, this in turn 
promotes the use of generic medicines which are mainly obtained from India as the main 
supplier of generic medicines. In addition, a report from BMI Research on Tanzania 
Pharmaceuticals and Healthcare (BMI, 2016) revealed that more than 90% of medicines 
circulating in the market in Tanzania were imported from overseas and majority of which 
were from India. These were consistent with findings of this study.  
 
Regardless of the country of manufacture of the finished pharmaceutical products, India 
and China were the leading sources of active pharmaceutical ingredients used in the 
medicines registered within the study period. This was consistent with the report on 
Market assessment on tools for U.S exporters (2016) which reported that most of the 
affordable active pharmaceutical ingredients and excipients used for finished products in 
the United States are manufactured in India and China. Several factors are known to 
contribute to this, including relatively low production costs, good government policies 
towards manufacturing and export business, as well as the availability of a large pool of 
skilled workers in these countries (Goldar & Parida, 2017). 
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From findings of this study, there was a clear shift in the trends in the registration of 
medicines as compared to the medicinal products proposed in standard treatment 
guidelines and essential medicine lists. These findings suggest that medicine selection 
and usage in developing countries may be influenced by other factors in addition to often 
static standard treatment guidelines. This finding indicates the need for regular updating 
of standard treatment guidelines so that they match the pace of advances in science and 
technology as well as public health needs. Registration of medicinal products that have 
been proposed in the standard treatment guidelines would ensure that  all medicines 
registered in Tanzania have undergone rigorous risk/benefit analysis, health technology 
assessment and consideration on relevance to public health  to enable full realization of 
the benefits as well as protection of public health. In many parts of the world including 
major and experienced jurisdictions such as those in the USA and United Kingdom, 
registration of medicines is not tied to its status in standard treatment guidelines. This 
allows innovation in disease areas in addition to those covered in treatment guidelines.  
 
Study findings have also revealed an overall high proportion of registered medicines 
being generics in the first year of study and all registered medicines as generics in the 
subsequent three years of the study. This re-affirms the preeminent position of generics in 
drug regimens in resource-limited countries such as Tanzania and is in line with emphasis 
on generic prescribing and dispensing that is advocated in the standard treatment 
guidelines of Tanzania (MOHCDGEC, 2018). Some of the advantages of using generic 
names in the prescribing of medicinal products include cost effectiveness, and the 
reduced potential for confusion when prescribing. A study by Manisha Das et al, (2017) 
aimed at evaluating the experience and attitude of patients who were consuming generic 
drugs reported no statistically significant difference in perception of quality and 
effectiveness among the patients who used generics and branded products, hence the use 
of generic medicines is well justified.  
 
The observed trend of majority of registered medicines being chemical medicines (97%) 
was contrary to what is observed in developed countries. Report on global biological 
market size and market (April 2018) indicated that approximately 50% of all new 
molecules approved in the USA were from the biological group of molecules. Increase in 
prevalence of noncommunicable and chronic diseases in these countries has been cited as 
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a major factor for the observed trend. It is also forecasted that during the period of 2018 
to 2026 there will be around 800 new biologicals approved, with biologicals accounting 
for approximately 25% of the total pharmaceutical market in 2016 (reference conversion 
newsletter).  
 
Despite documented an increasing prevalence of noncommunicable and chronic diseases 
in Tanzania (Mayinge et al, 2011), the decreasing trends in registration of biological 
medicines over the study years observed in this study could be attributed to the high costs 
of  biological medicines compared to the low purchasing capacity of individuals and the 
governments as it has been documented in the report from Health24 (2018) and the study 
from Erasmus L (2015). To address this challenge, Tanzania is on the verge of publishing 
for the first time the regulations aimed at facilitating the registration and availability of 
orphan medicines in the country. When approved and implemented, the likelihood is that 
the trend would be reversed, and an increase in the number of biological medicines made 
available for those patients in need.  
A trend towards the decrease in the registration of medicinal products intended for use in 
children was observed, and this seems to undermine the efforts made by the World Health 
Organization and other international organizations in bringing up the agenda of the 
development of pediatric only medicine formulations. Starting around the year 2012, 
these efforts had shown promising outcomes due to the fact that manufacturers in the 
European Union and USA have started formulating medicinal products that are indicated 
for exclusive use in pediatric age groups, however somehow manufacturers of these 
medicines have not considered their registration in Tanzania. The findings of this study 
did show an opposite trend to the trend seen in the European Union where the ten years 
report published in 2017 did show an overall increase in the approval of medicines for 
children in many therapeutic areas, most notably rheumatology and infectious diseases 
(EU, 2017). However, the same trend was seen in medicines for diseases which shows 
biological differences between adults and children, particularly rare diseases. 
 
Results on conformance of manufacturers to medicine registration requirements regarding 
the quality of the active pharmaceutical ingredients are consistent with the study by 
Isabella Ortega et al, (2014) where it was concluded that the most  frequent critical 
deficiencies were related to how the specific manufacturing process and the key materials 
used, in particular the API starting material, impact the API impurity content.  
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In this study, the number and pattern of APIMF deficiencies did not change over time 
during the study years, which may be attributed to the fact that due to their low volumes 
of purchase and need for cheaper APIs  most generic manufacturers are not able to obtain 
information on the quality of the APIs from respective manufacturers. Instead the 
materials are mostly obtained from vendors who would most of the time may be in 
possession of very limited and/or old data on open parts of the DMFs. As a result, the 
major areas such as synthesis and manufacture of the API and specifications and control 
of the API have been shown to have high proportions of overall deficiencies in across the 
years. 
 
With regards to the findings on the deficiencies in the FPP part of the studied 
applications, parts of the dossiers with overall highest proportions of findings over the 
years reflects the parts of the dossiers which are of critical importance to medicine 
evaluators and GMP inspectors. The section on manufacturing and process control of the 
FPP is much more scrutinized to ensure consistency of future production batches and 
specifications are more scrutinized to ensure accuracy in testing and validity of analytical 
methods, in addition specifications are viewed as a contractual document between the 
manufacturer and the regulators. Therefore increased scrutiny on these sections may 
explain why these sections of the submitted application dossiers have been found to have 
the higher proportion of deficiencies compared to other parts of the dossiers. The 
observed results are also consistent with the study by Zeleke et al, (2014) which reported 
that more deficiencies were from the areas of specifications of active pharmaceutical 
ingredients, development pharmaceutics, manufacturing methods and finished 
pharmaceutical products specifications.  
 
Notably, in all the years, the majority of deficiencies were observed from the sections on 
container closure systems of the finished product. This observation could be explained  
by the overall low GMP capacity among the manufacturers of finished pharmaceutical 
products from developing countries. A working paper from the Centre for Pharmaceutical 
Public Health Policy (2007) highlighted how GMP is perceived among manufacturers in 
India and Nepal and how these manufacturers perceive international GMP standards as 
being more stringent and restricting them from accessing international markets for their 
pharmaceutical products.  
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A gradual decrease in the time taken to register medicinal products as measured as time 
taken between the submission of the application for registration to the time the product 
obtains registration was observed. This could be attributed to the introduction of the CTD 
format for the compilation of applications for registration of medicines in Tanzania and in 
many other parts of the world. As documented by Mozlon (2010), the introduction of 
CTD influences the content of the review by imposing a consistent order of information 
and data, which results in shaping both the conduct of the review and the presentation of 
the results of the review, and hence promoting good review practices and increased 
efficiency.  
 
The observed trend in registration could also be attributed to an overall improvement in 
regulatory performance at the Tanzania Food and Drugs Authority which was catalyzed 
by the introduction of automated systems in the processing of medicine registration 
applications, GMP inspections and other support activities. Improvement in overall 
regulatory performance of TFDA have also been demonstrated from the findings of 
Benchmarking of TFDA regulatory systems by the World Health Organization in may 
2018 where TFDA had attained the Maturity Level 3 of its national medicine regulatory 
system pending clarification of few areas.  
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CHAPTER SIX 
CONCLUSION 
 
Findings of this study have for the first time highlighted the status of the medicine 
registration system in Tanzania. It is  clear that to some extent the system is capable of 
supporting the standard treatment guidelines of the country by making quality assured 
medicines available and by supporting the use of generic medicines. However, registration 
of biological medicines as well as medicines intended specifically for use in pediatric 
patients is on the decrease with no sign of reversal of the situation, and this could 
negatively impact the public health, particularly in the era of the increase in prevalence of 
noncommunicable diseases and chronic disease conditions in Tanzania. 
 
Despite the implementation of CTD guidelines on application for registration of medicinal 
products and strengthening of GMP inspections function by the TFDA, similar patterns in 
parts of medicinal products dossiers with deficiencies have been noted across the study 
years. These patterns were visible in both active pharmaceutical ingredient and finished 
pharmaceutical products part of the dossier. The high proportion of deficiencies identified 
still demonstrates weaknesses in the preparation of marketing authorization applications 
on the side of the applicant, furthermore, with regards to data on the quality of active 
pharmaceutical ingredients, special consideration needs to be made in ensuring that 
finished product manufacturers are in control of the quality of the active pharmaceutical 
ingredients that they use in their final dosage forms. 
 
The study has also revealed that initiatives made to strengthen the medicine registration 
system has produced positive results in terms of a decrease in overall timeline for 
registration of the product from the time that an application is made. Though the timeline 
in the final year of the study seems to be lower compared to other years where studied 
medicines were sampled, the timeline is still above the requirement of the clients’ service 
charter (2016) that has been established between TFDA and its clients. The observation 
could have been better if there was mechanism in place for tracking the exact time that the 
application stays with TFDA and the time taken by the applicant to address comments 
from the assessors. This therefore calls for establishment of robust medicine registration 
database that is capable of tracking registration timelines.  
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Annexure I: Data collection tool 
 
Part A: General and administrative information  
 
s/n Particular Response 
1 Application’s reference number  
2 International non-proprietary name 
of the product 
 
 
3 Dosage form  
4 Strength  
3 Applicant’s details” 
 
 
 Name:   
 Country:   
4 API (s) manufacturer details  
 Site address  
 Country  
5 API (s) manufacturer details  
 Site address  
 Country  
6 Local technical representative 
(name and address) 
 
7 Submission in CTD?   Yes: 
 
             No: 
8 Templates provided? QOS: 
 
BTIF: 
 
Biowaiver form: 
 
Not applicable: 
 
Part B: Trends in applications and registration 
s/n Particular Response 
1 Product type New chemical entity: 
 
Generic: 
2 Category Chemical drug: 
 
Vaccine: 
 
Biosimilar: 
 
Immunological product:  
3 Therapeutic indication  
4 Intended age group  
5 In standard treatment guideline?              Yes: 
 
            No: 
6 Indication per STG?              Yes: 
 
            No: 
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Part C: Deficiencies observed in submitted dossiers:  
S/n CTD Section Number of questions 
3.2.S Active Pharmaceutical Ingredient 
1 3.2.S.1   
3 3.S.2.1  
4 3.S.2.2  
5 
3.S.2.3 
 
6 
3.S.2.4 
 
7 3.S.3.1  
8 3.S.3.2  
9 3.S,4.1 & 4.5  
10 3.S,4.2 & 4.3  
11 3.S,4.4  
12 3.S,5  
13 3.S,6  
14 3.S,7  
 
S/n CTD Section Number of questions 
3.2.P Finished Pharmaceutical Product 
1 3.2.P.1   
2 3.2.P.2  
3 3.2.P.3  
4 3.2.P.4  
5 3.2.P.5  
6 3.2.P.6  
7 3.2.P.7  
8 3.2.P.8  
 
S/n CTD Section Number of questions 
1 Appendices   
2 Production documents  
 
S/n CTD Section Number of questions 
Bioequivalence 
1 Study rejected   
2 Study sites  
3 Study protocol and report  
4 Ethics  
5 Wrong comparator product  
6 Bioanalytical methods and 
analysis 
 
7 Statistics  
8 Handling of comparators  
9 Dissolution methods  
10 Quality assurance and monitoring  
11 Quality of the Biobatch  
12 Other  
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Part D:  Review of evaluation of assessment and registration timelines  
s/n Particular Response 
1 Date received  
2 Date first assessed 
 
 
3 Date second assessed (assumed to 
be date of dispatch of 
communication) 
 
4a Date of submission of response(s)   
5a Date of review of responses (date 
of second assessment or first 
assessment) 
 
4b Date of submission of response(s)   
5b Date of review of responses (date 
of second assessment or first 
assessment) 
 
4c Date of submission of response(s)   
5c Date of review of responses (date 
of second assessment or first 
assessment) 
 
6 Date of approval  
7 Number of variations since 
approval 
 
 
…………………………………….End……………………………………... 
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